Literature DB >> 15672937

Changing trends of prostate cancer in Asia.

Y S Pu1, H S Chiang, C C Lin, C Y Huang, K H Huang, J Chen.   

Abstract

Although Asian people have the lowest incidence and mortality rates of prostate cancer in the world, these rates have risen rapidly in the past two decades in most Asian countries. Prostate cancer has become one of the leading male cancers in some Asian countries. In 2000, the age-adjusted incidence was over 10 per 100000 men in Japan, Taiwan, Singapore, Malaysia, the Philippines and Israel. Although some of the increases may result from enhanced detection, much of the increased incidence may be associated with westernization of the lifestyle, with increasing obesity and increased consumption of fat. The differences in incidences between native Americans and Asian immigrants are getting smaller, reflecting a possible improvement of diagnostic efforts and changes of environmental risk factors in Asian immigrants. Nevertheless, the huge variations in incidences among ethnic groups imply that there are important genetic risk factors. The stage distributions of prostate cancer in Asian populations are still unfavorable compared to those of Western developed countries. However, a trend towards diagnosing cancer with more favorable prognosis is seen in most Asian countries. Both genetic and environmental risk factors responsible for elevated risks in Asian people are being identified, which may help to reduce prostate cancer incidence in a chemopreventive setting.

Entities:  

Mesh:

Year:  2004        PMID: 15672937     DOI: 10.1080/13685530412331284687

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  34 in total

1.  Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial.

Authors:  Seng-Fah Tong; Chirk-Jenn Ng; Boon-Cheok Lee; Verna-K M Lee; Ee-Ming Khoo; Eng-Giap Lee; Hui-Meng Tan
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

Review 2.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

3.  Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

4.  The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer.

Authors:  Edmond P H Choi; Carlos K H Wong; Eric Y F Wan; James H L Tsu; W Y Chin; Kenny Kung; M K Yiu
Journal:  Qual Life Res       Date:  2016-02-23       Impact factor: 4.147

5.  Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients.

Authors:  Yuki Kita; Yosuke Shimizu; Takahiro Inoue; Tomomi Kamba; Koji Yoshimura; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2012-07-13       Impact factor: 3.402

6.  Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy.

Authors:  T-H Kim; Y-S Ha; S H Choi; E S Yoo; B W Kim; S-J Yun; W-J Kim; Y S Kwon; T G Kwon
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

7.  Robotic-assisted radical prostatectomy by a single surgeon in Taiwan: experience with the initial 30 cases.

Authors:  Yen-Chuan Ou; Chi-Rei Yang; John Wang; Chen-Li Cheng; Vipul R Patel
Journal:  J Robot Surg       Date:  2008-08-26

8.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

9.  Febrile infection in post-prostate biopsy: results of a ten-year single-institution study in South Taiwan.

Authors:  Yuh-Shyan Tsai; Chia-Hong Chen; Yeong-Chin Jou; Wen-Horng Yang; Chien-Chen Chang; Tzong-Shin Tzai
Journal:  Surg Infect (Larchmt)       Date:  2013-11-27       Impact factor: 2.150

10.  Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.

Authors:  Yasutomo Nakai; Kazuo Nishimura; Masashi Nakayama; Motohide Uemura; Hitoshi Takayama; Norio Nonomura; Akira Tsujimura
Journal:  Int J Clin Oncol       Date:  2013-03-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.